The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
Hypoglycemia Upon Hospital Admission From Long-term Care: Health Care Resource Use
This analysis of a hospital billing database describes inpatient length of stay, intensive care unit length of stay, comorbidities, and costs for patients with diabetes after admission with hypoglycemia from long-term care or home.
Insulin Analogs, Pen Delivery Devices Most Used Among Patients With T2D
Using data from a nationally representative sample, investigators sought to determine trends in insulin device use.
Light Drinking Linked With Lower Risk of Type 2 Diabetes for Some Women
Some alcohol, but not more than 1 drink per day, was linked to a 55% lower risk of type 2 diabetes in women with a history of gestational diabetes.
Study Finds Statin Use Associated With Diabetes Progression
Using electronic medical record data from Veterans Affairs, researchers found statin use was associated with a greater risk of diabetes progression.
Patient and Supporter Factors Affecting Engagement With Diabetes Telehealth
Family support with medication management and recent urgent self-management concerns are 2 novel factors, among others, that predict completion of diabetes telehealth calls.
Diabetic Nephropathy, Obesity Increase COVID-19 Mortality Risk in Patients With Type 2 Diabetes
Patients with T2D had elevated blood glucose levels but there were no notable differences in levels between surviving and non-surviving patients with T2D.
Dr Deepak Bhatt on the Importance of In-Hospital Initiation of SGLT2 Inhibitors
Deepak L. Bhatt, MD, MPH, outlines the benefits of starting patients on sodium glucose co-transporter 2 (SGLT2) inhibitors while they are hospitalized.
Medicaid Expansion Linked With Reduction in Uninsurance and Improved Blood Pressure, Glucose Control Measures
Results of a representative study of patients at federally qualified health centers found Medicaid expansion was associated with reduced rates of uninsurance, improved blood pressure and diabetes control measures, and progress in closing racial care disparities over 5 years.
Managing the Surge: Delayed Chronic Wound Care During COVID-19
Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says
New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.
Presentation Outlines Long-term CV Risks of Gestational Diabetes
A session at the 5th annual Heart in Diabetes Conference highlights the long-term risks of gestational diabetes.
Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19
New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.
FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF
The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.
Dr David McIntyre on Care Takeaways From COVID-19 for Pregnant Patients With Diabetes
David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.
Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period
Native American and Black youth aged 10 to 19 years had the highest incidence of type 2 diabetes overall.
Dr Deepak L. Bhatt Discusses SGLT Inhibitors’ Impact on Glycemic Control
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.
USPSTF Lowers Recommended T2D, Prediabetes Screening Age to 35 Years
The United States Preventive Services Task Force (USPSTF) lowered its recommended screening age for type 2 diabetes and prediabetes from 40 to 35 years among overweight and obese individuals.
Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes
Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
FDA Approves Empagliflozin to Treat HFrEF Regardless of T2D Status
The FDA has approved empagliflozin (Jardiance) for adults with heart failure with reduced ejection fraction, regardless of type 2 diabetes status.
Jump in US Gestational Diabetes Rates Seen Across All Racial, Age Groups
An analysis of gestational diabetes trends in the United States revealed increases across all age and racial subgroups over the past decade.
Catlin Dennis Outlines Lessons Learned From COVID-19 for Vulnerable Youth With Diabetes
Catlin Dennis, MPH, explains the importance of securing internet and technology access among vulnerable youth with diabetes.
Dr Bobeck Modjtahedi Discusses Trends in Telehealth for Diabetic Retinopathy
Bobeck Modjtahedi, MD, elaborates on the importance of devising effective and convenient mechanisms for diabetic retinopathy screening.
SGLT2 Inhibitors Cut Cardiovascular Risk in Diabetes, Even in Low-risk Populations
The new report compared the benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors with those of other glucose-lowering drugs and found lower rates of heart disease and mortality.
Antidepressant Adherence Linked With Lower Risk of Advanced Diabetic Complications
Regular use of selective serotonin reuptake inhibitors or tricyclic or tetracyclic antidepressants was associated with a reduced risk of all-cause mortality in patients with diabetes.
Dr David McIntyre Describes the Intersection Between COVID-19, Obesity, and Gestational Diabetes
David McIntyre, MD, FRACP, outlines how metabolic factors could impact the severity of COVID-19 infections among pregnant people.
Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease
Dr Deepak Bhatt on the Potential Stroke Benefits of SGLT1s
Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, discusses whether sodium glucose co-transporter 1 (SGLT1) inhibitors can yield stroke benefits in patients with type 2 diabetes.
Biking Linked With Reduced All-Cause, CVD Mortality Among Patients With Diabetes
New research shows that independent of other forms of physical activity, biking is associated with reduced mortality rates among adults with diabetes.
Catlin Dennis Explains Challenges Vulnerable Youth With Diabetes Faced During COVID-19
Catlin Dennis, MPH, describes the challenges socially and medically vulnerable youth with diabetes and their families faced during the COVID-19 pandemic.
Dr Michelle Litchman Outlines the Benefits of Online Diabetes Peer Support Groups
Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, describes the results of a study that looked at diabetes technology use and online peer support systems among Spanish-speaking patients. Findings showed that when these 2 interventions are used in conjunction, a positive feedback loop forms.
2 Clarke Drive Cranbury, NJ 08512